Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023

14 April, 2023 -- Root, Switzerland -- Novocure today announced 27 presentations on Tumour Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida.

The research described in the presentations includes real-world evidence supporting the safety and efficacy of TTFields therapy in glioblastoma (GBM) and preclinical research spanning 15 tumor types suggesting the broad applicability and effectiveness of TTFields alone and together with other therapies.

Presentation highlights include research on:

• the largest global post-marketing safety dataset of more than 25,000 TTFields-treated patients with high-grade glioma from the last decade demonstrating the safety and broad applicability of TTFields therapy regardless of diagnosis, age or sex
• a systematic review and meta-analysis examining the overall survival (OS) benefit of TTFields therapy in newly diagnosed GBM, finding improved overall survival for TTFields-treated patients relative to those not treated with TTFields, and demonstrating that ≥ 75% average TTFields use was consistently associated with longer survival relative to < 75% average TTFields use
• preclinical investigations that demonstrated TTFields with cisplatin or paclitaxel increased the effectiveness of both chemotherapies in cervical cancer cells
• in vitro and in vivo investigations of TTFields for treatment of spinal metastasis provides first evidence that TTFields could become an effective therapy for spinal metastasis
• TTFields selectively enhanced cancer cell membrane permeability, while not affecting normal cells, improving doxorubicin accumulation in vitro and in vivo breast cancer models
• adding TTFields to the PULSAR paradigm for radiotherapy and demonstrating it is most effective when added prior to each radiation dose, an effect that is enhanced when also used with an immune checkpoint inhibitor
• the application of the ability of TTFields to induce a state of BRCAness (DNA repair deficiency) in ovarian cancer cell lines, and combining TTFields with either carboplatin or PARP inhibitors: demonstrating that TTFields display a synergistic interaction with either of these drugs in a wild type ovarian cell line, and an additive effect in a BRCA mutant cell line

“Through ongoing research, we continue to discover that TTFields therapy has great potential for applicability across many solid tumour types and concomitant use with other therapies,” said Moshe Giladi, Novocure’s Chief Science Officer. “We are honoured to share new insights about TTFields therapy and participate in the exchange of scientific information with researchers from around the world at the AACR Annual Meeting.”

About TTFields Therapy

Tumour Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumour types when used with chemotherapy, radiotherapy, immune checkpoint inhibition or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumours. To learn more about Tumour Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.

About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialisation of its innovative therapy, Tumour Treating Fields. Novocure’s commercialised products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumour Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centres in Portsmouth, New Hampshire and Tokyo, as well as a research centre in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.